Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Epirubicin hydrochloride
Drug ID BADD_D00785
Description An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Indications and Usage For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Marketing Status approved
ATC Code L01DB03
DrugBank ID DB00445
KEGG ID D02214
MeSH ID D015251
PubChem ID 65348
TTD Drug ID D0C9XJ
NDC Product Code 0143-9202; 0009-5091; 0009-5093; 77391-002; 0143-9203
UNII 22966TX7J5
Synonyms Epirubicin | 4'-Epidoxorubicin | 4' Epidoxorubicin | 4'-Epi-Doxorubicin | 4' Epi Doxorubicin | 4'-Epi-Adriamycin | 4' Epi Adriamycin | 4'-Epiadriamycin | 4' Epiadriamycin | 4'-Epi-DXR | 4' Epi DXR | EPI-cell | EPI cell | EPIcell | Epilem | Farmorubicina | IMI-28 | IMI 28 | IMI28 | NSC-256942 | NSC 256942 | NSC256942 | Ellence | Pharmorubicin | Farmorubicine | Farmorubicin | Epirubicin Hydrochloride | Hydrochloride, Epirubicin
Chemical Information
Molecular Formula C27H29NO11.ClH
CAS Registry Number 25316-40-9
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O .Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cough22.02.03.001--
Dehydration14.05.05.001--
Dermatitis23.03.04.002---
Dermatitis atopic10.01.04.004; 23.03.04.016---
Dermatitis bullous23.03.01.002--
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.001---
Drug interaction08.06.03.001---
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysaesthesia17.02.06.003; 23.03.03.077--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Dyspnoea exertional02.11.05.005; 22.02.01.005---
Dysuria20.02.02.002--
Embolism venous24.01.01.003---
Epistaxis22.04.03.001; 24.07.01.005--
Erythema23.03.06.001---
Erythema multiforme10.01.03.015; 23.03.01.003--
Eye disorder06.08.03.001---
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Fatigue08.01.01.002--
Febrile neutropenia01.02.03.002; 08.05.02.004--
Feeling abnormal08.01.09.014---
Flatulence07.01.04.002--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages